News Column

CORRECTED DATE FOR Q2 CONFERENCE CALL: Compugen Second Quarter 2014 Conference Call Scheduled for Wednesday, August 6, 2014 at 10:00 AM EDT

July 31, 2014

TEL AVIV, Israel--(BUSINESS WIRE)-- Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Wednesday, August 6, 2014 to review the second quarter 2014 results. The quarterly results will be released on the Companyís website (, prior to the conference call. A previous release stating August 5 as the date for the call was in error.

To access the conference call, please dial 1-888-281-1167 from the US, or + 972-3-918-0610 internationally.†The call will also be available via live webcast located at the following link.

A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-877-456-0009 from the US or +972-3-925-5925 internationally. The replay will be available through August 8, 2014.

About Compugen

Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology.†The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the†in silico†(by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. Compugenís wholly-owned U.S. subsidiary located in South San Francisco is developing oncology and immunology monoclonal antibody therapeutic candidates against its drug targets. For additional information, please visit Compugen's corporate website at

Compugen Ltd.

Tsipi Haitovsky

Global Media Liaison


Source: Compugen Ltd.

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Business Wire

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters